As of January 2018, the MPP has signed agreements with nine patent holders for thirteen HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and two hepatitis C direct-acting antivirals. Twenty generic manufacturers and product developers have now signed MPP sublicensing agreements.
The recent presentation above is highlighting the progress of MPP’s generic partners in developing MPP-licensed medicines. It provides an overview of manufacturer filing timelines per combination, countrywide filing status and plans for registration, as well as the latest impact data from MPP’s agreements. Generic competition is making a difference in fostering lower prices and improving treatment coverage. MPP’s partners have distributed 14.6 million patient years of HIV and hepatitis C products saving international procurers $391 million (Jan. 2012-June 2017).